JP2016534153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534153A5 JP2016534153A5 JP2016547977A JP2016547977A JP2016534153A5 JP 2016534153 A5 JP2016534153 A5 JP 2016534153A5 JP 2016547977 A JP2016547977 A JP 2016547977A JP 2016547977 A JP2016547977 A JP 2016547977A JP 2016534153 A5 JP2016534153 A5 JP 2016534153A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- administration
- subject
- powder
- additive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- 239000000654 additive Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- 230000000996 additive effect Effects 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 229960003136 leucine Drugs 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000004067 bulking agent Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 235000019454 L-leucine Nutrition 0.000 claims 1
- 239000004395 L-leucine Substances 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 239000004469 amino acid formulation Substances 0.000 claims 1
- 230000009084 cardiovascular function Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 125000000647 trehalose group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361889887P | 2013-10-11 | 2013-10-11 | |
| US61/889,887 | 2013-10-11 | ||
| PCT/US2014/060039 WO2015054574A1 (en) | 2013-10-11 | 2014-10-10 | Spray dry formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019024568A Division JP6823095B2 (ja) | 2013-10-11 | 2019-02-14 | 噴霧乾燥製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534153A JP2016534153A (ja) | 2016-11-04 |
| JP2016534153A5 true JP2016534153A5 (enExample) | 2017-11-16 |
| JP6483714B2 JP6483714B2 (ja) | 2019-03-13 |
Family
ID=52813663
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547977A Active JP6483714B2 (ja) | 2013-10-11 | 2014-10-10 | 噴霧乾燥製剤 |
| JP2019024568A Active JP6823095B2 (ja) | 2013-10-11 | 2019-02-14 | 噴霧乾燥製剤 |
| JP2021001507A Pending JP2021063119A (ja) | 2013-10-11 | 2021-01-07 | 噴霧乾燥製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019024568A Active JP6823095B2 (ja) | 2013-10-11 | 2019-02-14 | 噴霧乾燥製剤 |
| JP2021001507A Pending JP2021063119A (ja) | 2013-10-11 | 2021-01-07 | 噴霧乾燥製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9925184B2 (enExample) |
| EP (1) | EP3054937B1 (enExample) |
| JP (3) | JP6483714B2 (enExample) |
| CN (2) | CN111743901B (enExample) |
| AU (3) | AU2014331796B2 (enExample) |
| CA (1) | CA2926793C (enExample) |
| ES (1) | ES2959419T3 (enExample) |
| WO (1) | WO2015054574A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| WO2014110200A1 (en) | 2013-01-10 | 2014-07-17 | Zisman Lawrence S | Non-selective kinase inhibitors |
| CN105473133A (zh) | 2013-04-30 | 2016-04-06 | 欧缇托匹克公司 | 干粉制剂及使用方法 |
| US9469600B2 (en) | 2013-10-25 | 2016-10-18 | Insmed Incorporated | Prostacyclin compounds, compositions and methods of use thereof |
| US10343979B2 (en) | 2014-11-18 | 2019-07-09 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| IL260823B2 (en) * | 2016-01-29 | 2024-08-01 | Mannkind Corp | Dry powder inhaler |
| EP3452170A4 (en) * | 2016-05-05 | 2020-04-01 | Liquidia Technologies, Inc. | TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION |
| GB201609940D0 (en) * | 2016-06-07 | 2016-07-20 | Novabiotics Ltd | Microparticles |
| JP2019518049A (ja) * | 2016-06-17 | 2019-06-27 | ユナイテッド セラピューティクス コーポレイション | 高い効能を有する細胞外小胞 |
| RU2763525C2 (ru) * | 2016-10-27 | 2021-12-30 | Пульмокин, Инк. | Комбинированная терапия для лечения легочной гипертензии |
| CA3076353A1 (en) | 2017-09-22 | 2019-03-28 | Otitopic Inc. | Dry powder compositions with magnesium stearate |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| US20210038510A1 (en) * | 2018-02-08 | 2021-02-11 | Pulmokine, Inc. | Formulations of kinase inhibitors and prostanoids |
| JP7090941B2 (ja) * | 2018-10-02 | 2022-06-27 | 学校法人 名城大学 | 吸入粉末剤、その評価方法及びその用途 |
| CN119632930A (zh) | 2019-04-29 | 2025-03-18 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| US11413289B2 (en) | 2019-05-16 | 2022-08-16 | Aerovate Therapeutics, Inc. | Inhalable imatinib formulations, manufacture, and uses thereof |
| US11464776B2 (en) | 2019-05-16 | 2022-10-11 | Aerovate Therapeutics, Inc. | Inhalable imatinib formulations, manufacture, and uses thereof |
| EP4069069A4 (en) | 2020-01-11 | 2024-07-03 | Third Pole, Inc. | SYSTEMS AND METHODS FOR NITROGEN OXIDE PRODUCTION WITH HUMIDITY CONTROL |
| JPWO2021201258A1 (enExample) * | 2020-04-01 | 2021-10-07 | ||
| JP2023550463A (ja) * | 2020-11-23 | 2023-12-01 | エアロベイト セラピューティクス， インコーポレイテッド | イマチニブ処方物、その製造および使用 |
| KR20240006513A (ko) * | 2021-05-07 | 2024-01-15 | 지비002 인코포레이티드 | N-3-[(1s)-1-[6-(3,4-다이메톡시페닐)피라진-2-일]아미노에틸]페닐-5-메틸피리딘-3-카복사마이드의 결정질 형태 및 관련 생성물 및 방법 |
| EP4568692A1 (en) | 2022-08-10 | 2025-06-18 | GB002, Inc. | Tyrosine kinase inhibitor and activin type 2 receptor antagonist combination therapy for treating pulmonary arterial hypertension (pah) |
| WO2026151681A1 (en) | 2025-01-09 | 2026-07-16 | Gb002, Inc. | Combination therapy for treating interstitial lung disease |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4118401A (en) | 1977-10-19 | 1978-10-03 | American Hoechst Corporation | Preparation of 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid and precursors therefor |
| JPS5488231A (en) | 1977-12-22 | 1979-07-13 | Sumitomo Chem Co Ltd | 3-phenyloxymethylaniline derivative, its preparation, and herbicides consisting of it |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| DE3632329A1 (de) | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| US5648369A (en) | 1991-11-20 | 1997-07-15 | University Of Kentucky Research Foundation | Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists |
| SK27198A3 (en) | 1995-08-30 | 1998-09-09 | Bayer Ag | Acylaminosalicylic acid amides and their uses as pesticides |
| JPH09268169A (ja) | 1996-04-01 | 1997-10-14 | Otsuka Chem Co Ltd | サリチル酸アニリド誘導体、それを有効成分として含む植物病害防除剤 |
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| CA2382821A1 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| US6451830B1 (en) | 1999-09-23 | 2002-09-17 | G.D. Searle & Co. | Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity |
| AU778042B2 (en) | 1999-10-19 | 2004-11-11 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2001029025A2 (en) | 1999-10-19 | 2001-04-26 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| AU778417B2 (en) | 2000-02-25 | 2004-12-02 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| AUPS251502A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Protein kinase inhibitors |
| CA2486183C (en) | 2002-05-23 | 2012-01-10 | Cytopia Pty Ltd. | Protein kinase inhibitors |
| ATE408583T1 (de) | 2002-05-23 | 2008-10-15 | Cohen Ben Z | Medizinisch genaues pumpsystem |
| ATE457025T1 (de) | 2002-05-23 | 2010-02-15 | Cytopia Res Pty Ltd | Kinaseinhibitoren |
| DK1522314T3 (da) | 2002-06-26 | 2014-05-26 | Ono Pharmaceutical Co | Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse |
| JP2005538975A (ja) | 2002-07-03 | 2005-12-22 | アステックス テクノロジー リミテッド | ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体 |
| EP1542699A4 (en) | 2002-07-15 | 2009-03-25 | Myriad Genetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF |
| JP4942297B2 (ja) | 2002-10-25 | 2012-05-30 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用 |
| AU2002953255A0 (en) | 2002-12-11 | 2003-01-02 | Cytopia Research Pty Ltd | Protein kinase inhibitors |
| WO2005002673A1 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
| US20050026879A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| FR2858459B1 (fr) | 2003-08-01 | 2006-03-10 | Commissariat Energie Atomique | Commutateur micro-mecanique bistable, methode d'actionnement et procede de realisation correspondant |
| ATE455546T1 (de) | 2003-08-06 | 2010-02-15 | Vertex Pharma | Aminotriazol-verbindungen als proteinkinase- hemmer |
| JP4823914B2 (ja) | 2003-11-07 | 2011-11-24 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｆｇｆｒ３の阻害および多発性骨髄腫の治療 |
| GB2423083B (en) | 2003-12-03 | 2007-07-11 | Cytopia Res Pty Ltd | Azole-based kinase inhibitors |
| PT1689715E (pt) | 2003-12-03 | 2011-05-16 | Ym Biosciences Australia Pty | Inibidores da tubulina |
| ES2389203T3 (es) | 2004-01-12 | 2012-10-24 | Ym Biosciences Australia Pty Ltd | Inhibidores de quinasa selectivos |
| US20080268460A1 (en) | 2004-05-20 | 2008-10-30 | Wyeth | Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases |
| JP2006111553A (ja) | 2004-10-13 | 2006-04-27 | Dainippon Sumitomo Pharma Co Ltd | スルホニルオキシインドール誘導体及びそれを含有する医薬組成物 |
| CA2628847A1 (en) | 2005-11-10 | 2007-05-18 | Bayer Healthcare Ag | Diaryl ureas for treating pulmonary hypertension |
| WO2007087575A2 (en) | 2006-01-24 | 2007-08-02 | University Of Chicago | Compositions and methods for treating pulmonary hypertension |
| BRPI0708347A2 (pt) | 2006-02-28 | 2011-05-24 | Cytopia Res Pty Ltd | inibição jak2 como um tratamento da hipertensão arterial pulmonar |
| WO2007124382A2 (en) * | 2006-04-19 | 2007-11-01 | Novartis Vaccines And Diagnostics, Inc. | Inhaled imipenem |
| PL2848610T3 (pl) * | 2006-11-15 | 2018-01-31 | Ym Biosciences Australia Pty | Inhibitory aktywności kinazy |
| BRPI0811516A2 (pt) | 2007-05-04 | 2014-11-18 | Irm Llc | Compostos e composições como inibidores de c-kit e pdgfr cinase |
| CA2686378C (en) | 2007-05-04 | 2012-07-24 | Irm Llc | Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors |
| AU2008289037B2 (en) | 2007-08-22 | 2012-03-01 | Novartis Ag | 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors |
| EA017392B1 (ru) | 2007-08-22 | 2012-12-28 | Айрм Ллк | Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ |
| HRP20120457T1 (hr) | 2007-12-20 | 2012-06-30 | Bayer Pharma Aktiengesellschaft | 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba |
| KR20110053354A (ko) | 2008-08-13 | 2011-05-20 | 노파르티스 아게 | 폐동맥 고혈압의 치료 |
| DE102009004197A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung |
| WO2010102065A1 (en) | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
| WO2010132827A1 (en) | 2009-05-15 | 2010-11-18 | Bend Research, Inc. | Low-molecular dextran for powder inhalations |
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| WO2012031129A2 (en) | 2010-09-03 | 2012-03-08 | Bend Research, Inc. | Spray-drying apparatus and methods of using the same |
| US9248584B2 (en) | 2010-09-24 | 2016-02-02 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| SG195038A1 (en) | 2011-05-19 | 2013-12-30 | Savara Inc | Dry powder vancomycin compositions and associated methods |
| US8569283B2 (en) | 2011-09-01 | 2013-10-29 | Valentina Molteni | Compounds and compositions as c-Kit kinase inhibitors |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| JP2016506417A (ja) * | 2013-01-10 | 2016-03-03 | プルモキネ、インコーポレイテッド | キナーゼ阻害剤の治療指標 |
| WO2014110200A1 (en) * | 2013-01-10 | 2014-07-17 | Zisman Lawrence S | Non-selective kinase inhibitors |
| CA3280124A1 (en) | 2013-07-31 | 2025-10-31 | Avalyn Pharma Inc. | Aerosol imatinib compounds and uses thereof |
| WO2015179369A1 (en) | 2014-05-20 | 2015-11-26 | Infinity Pharmaceuticals, Inc. | Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors |
-
2014
- 2014-10-10 ES ES14852309T patent/ES2959419T3/es active Active
- 2014-10-10 CA CA2926793A patent/CA2926793C/en active Active
- 2014-10-10 CN CN202010266778.2A patent/CN111743901B/zh active Active
- 2014-10-10 US US15/028,347 patent/US9925184B2/en active Active
- 2014-10-10 JP JP2016547977A patent/JP6483714B2/ja active Active
- 2014-10-10 EP EP14852309.5A patent/EP3054937B1/en active Active
- 2014-10-10 WO PCT/US2014/060039 patent/WO2015054574A1/en not_active Ceased
- 2014-10-10 AU AU2014331796A patent/AU2014331796B2/en active Active
- 2014-10-10 CN CN201480067999.XA patent/CN106132403B/zh active Active
-
2017
- 2017-11-10 US US15/809,054 patent/US20180193336A1/en not_active Abandoned
-
2019
- 2019-02-14 JP JP2019024568A patent/JP6823095B2/ja active Active
-
2020
- 2020-04-16 AU AU2020202556A patent/AU2020202556A1/en not_active Abandoned
-
2021
- 2021-01-07 JP JP2021001507A patent/JP2021063119A/ja active Pending
-
2022
- 2022-05-27 AU AU2022203611A patent/AU2022203611A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534348A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2016512248A5 (enExample) | ||
| JP2015057436A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| JP2011502997A5 (enExample) | ||
| JP2012503668A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| MX2013013503A (es) | Composiciones de vancomicina en polvo seco y metodos asociados. | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| JP2016534142A5 (enExample) | ||
| JP2019507781A5 (enExample) | ||
| JP2019528320A5 (enExample) | ||
| JP2015525763A5 (enExample) | ||
| HK1203149A1 (en) | Novel dosage form and formulation of abediterol | |
| JP2016510326A5 (enExample) | ||
| FI3710036T3 (fi) | Stabiileja askorbiinihappokoostumuksia ja menetelmiä niiden käyttämiseksi | |
| CA3019769C (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| JP2016534081A5 (ja) | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 | |
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. | |
| JP2015510916A5 (enExample) | ||
| JP2016516773A5 (enExample) | ||
| JP2017532316A5 (enExample) | ||
| RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона |